Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An announcement from Qiagen ( (QGEN) ) is now available.
Qiagen has disclosed a manager’s transaction involving Thierry Bernard, a member of its managing body, under market abuse regulations. The filing reports the release of 900 performance stock units granted in 2016 and the subsequent receipt of 460 common shares through a net share settlement conducted outside a trading venue.
The transaction, which involved shares withheld to cover taxes and related costs, is linked to the exercise of a long-term share-based incentive program. This disclosure underscores Qiagen’s adherence to transparency requirements around executive equity compensation and provides investors with visibility into management’s alignment with shareholder interests through stock-based rewards.
The most recent analyst rating on (QGEN) stock is a Buy with a $58.00 price target. To see the full list of analyst forecasts on Qiagen stock, see the QGEN Stock Forecast page.
More about Qiagen
Qiagen N.V. is a Netherlands-based life sciences and molecular diagnostics company that develops and supplies sample and assay technologies for molecular testing. Its products are used in clinical diagnostics, pharmaceutical research, and applied testing, and its shares are listed in Frankfurt and on several other European exchanges as well as the NYSE and Swiss markets.
Average Trading Volume: 2,173,009
Technical Sentiment Signal: Strong Buy
Current Market Cap: $10.1B
For an in-depth examination of QGEN stock, go to TipRanks’ Overview page.